By impairing the reactivation of these enhancers leaving unopposed BCL6 oncogenic activity, CREBBP loss of function disrupt the expression of immune synapse genes and their downstream signaling pathways, resulting in accumulation of aberrant GC B cells that fail to properly respond to exit signals from the GC microenvironment thereby promoting lymphoma progression. The gene discussed is CREBBP; the disease is lymphoma.